
71-58-9
- Product Name:Medroxyprogesterone Acetate
- Molecular Formula:C24H34O4
- Purity:99%
- Molecular Weight:386.532
Product Details;
CasNo: 71-58-9
Molecular Formula: C24H34O4
Appearance: white crystalline powder
Buy High Quality High Purity 99% Medroxyprogesterone Acetate 71-58-9 Best Price
- Molecular Formula:C24H34O4
- Molecular Weight:386.532
- Appearance/Colour:white crystalline powder
- Vapor Pressure:3.85E-10mmHg at 25°C
- Melting Point:206-207 °C(lit.)
- Refractive Index:48 ° (C=1, Dioxane)
- Boiling Point:496.4 °C at 760 mmHg
- Flash Point:213.2 °C
- PSA:60.44000
- Density:1.13 g/cm3
- LogP:4.51270
Medroxyprogesterone 17-acetate(Cas 71-58-9) Usage
Description |
Medroxyprogesterone acetate (MPA) is an odorless, white to off-white microcrystalline powder, and a synthetic derivative of the sex hormone progesterone. |
Uses |
Medroxyprogesterone acetate (MPA) serves multiple roles including a contraceptive, hormone replacement therapy, and treatment for endometriosis. MPA effectively prevents fertilization and accelerates egg transport in female ferrets when administered before ovulation, and reversibly blocks ovulation in rats. It exhibits anti-androgenic and immunosuppressive properties and has been utilized to treat various conditions such as dysfunctional uterine bleeding, secondary amenorrhea, and certain carcinomas. MPA is also used in veterinary medicine to manage sexually dimorphic behavior in cats. Despite its clinical benefits, it is a suspected carcinogen with various human and experimental adverse effects reported, including reproductive and teratogenic impacts. MPA is sensitive to air and light and needs protection to maintain its stability. |
InChI:InChI=1/C24H34O4/c1-13-10-17-18(23(4)8-6-16(27)11-19(13)23)7-9-24(5)20(17)12-21(28-15(3)26)22(24)14(2)25/h11,13,17-18,20-22H,6-10,12H2,1-5H3
71-58-9 Relevant articles
Preparation method of medroxyprogesterone acetate for perimenopausal syndrome
-
, (2022/03/17)
The invention relates to a preparation m...
Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?
Frank Z. Stanczyk a c, Bhagu R. Bhavnani b
The Journal of Steroid Biochemistry and Molecular Biology Volume 142, July 2014, Pages 30-38
The negative results of large clinical studies employing combined HT with medroxyprogesterone acetate and CEE in postmenopausal women has called into question the safety of medroxyprogesterone acetate. This review examines the pharmacokinetics and metabolism of medroxyprogesterone acetate, which can be altered by a variety of factors in the age group of women using HT to produce potential changes in potency. It also looks at the effects of MPA on the breast, cardiovascular system, and brain, to examine whether there is evidence for an increase in risk of diseases
Oral Medroxyprogesterone Acetate and Combination Oral Contraceptives for Acute Uterine Bleeding A Randomized Controlled Trial
Munro, Malcolm G. MD1,3; Mainor, Nakia MD1; Basu, Romie MD1; Brisinger, Mikael MD2; Barreda, Lorena1
Obstetrics & Gynecology 108(4):p 924-929, October 2006.
Forty patients were randomly assigned, 20 in each group; 33 were evaluated at the 14-day visit. Emergency surgical procedures were avoided in 100% of those women taking medroxyprogesterone acetate and 95% of the OC group. Cessation of bleeding had occurred in 88% of the OC group and 76% of those receiving medroxyprogesterone acetate, with a median time to bleeding cessation of 3 days for both groups. Compliance with therapy was higher in the medroxyprogesterone acetate group than the OC group, but there was no overall difference in the incidence of treatment-related nausea and bloating.
71-58-9 Process route
-
- 32634-95-0
17α-Acetoxy-6-methylene-pregn-4-ene-3,20-dione

-
- 71-58-9
Medroxyprogesterone acetate
Conditions | Yield |
---|---|
With ethanol; 5%-palladium/activated carbon; In cyclohexene; at 75 - 78 ℃; for 5h; Reagent/catalyst; Temperature;
|
87.5% |
With sodium acetate; cyclohexene; palladium on activated charcoal; In ethanol; water; Heating / reflux;
|
-
- 986-96-9
3,17-diacetoxy-6-methyl-pregna-3,5-dien-20-one

-
- 71-58-9
Medroxyprogesterone acetate
Conditions | Yield |
---|---|
With hydrogenchloride;
|
|
With hydrogenchloride; In methanol; water; at 50 ℃; Solvent; Reagent/catalyst; Temperature;
|
71-58-9 Upstream products
-
2381-48-8
6-methylpregn-5-ene-3β,17α-diol-20-one 17-acetate
-
986-96-9
3,17-diacetoxy-6-methyl-pregna-3,5-dien-20-one
-
520-85-4
Medroxyprogesterone
-
108-24-7
acetic anhydride
71-58-9 Downstream products
-
595-33-5
Megestrol acetate
-
57-16-9
17α-acetoxy-3β-hydroxy-6α-methylpregn-4-en-20-one
-
69688-15-9
17α-acetoxy-6α-methyl-5β-pregnane-3,20-dione
-
1104-99-0
3-Methoxy-6-methyl-17α-acetoxy-pregnadien-(3,5)-on-(20)
Relevant Products
-
Methyl trans-4-aminocyclohexanecarboxylate hydrochloride
CAS:61367-07-5
-
2-Butyl-3-(4-methoxybenzoyl)-5-nitrobenzofuran
CAS:141627-42-1